🚀 VC round data is live in beta, check it out!
Joincare Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Joincare Pharmaceutical and similar public comparables like Supernus Pharmaceuticals, Tango Therapeutics, Walvax Biotechnology, Apeloa Pharmaceutical and more.
Joincare Pharmaceutical Overview
About Joincare Pharmaceutical
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
Founded
1992
HQ
Employees
9.8K
Website
Sectors
Financials (LTM)
EV
$1B
Joincare Pharmaceutical Financials
Joincare Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $360M.
In the same LTM period, Joincare Pharmaceutical generated $1B in gross profit, $360M in EBITDA, and $200M in net income.
Revenue (LTM)
Joincare Pharmaceutical P&L
In the most recent fiscal year, Joincare Pharmaceutical reported revenue of $2B and EBITDA of $625M.
Joincare Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $360M | XXX | $625M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $200M | XXX | $196M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Joincare Pharmaceutical Stock Performance
Joincare Pharmaceutical has current market cap of $3B, and enterprise value of $1B.
Market Cap Evolution
Joincare Pharmaceutical's stock price is $1.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $3B | -1.0% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJoincare Pharmaceutical Valuation Multiples
Joincare Pharmaceutical trades at 0.6x EV/Revenue multiple, and 3.8x EV/EBITDA.
EV / Revenue (LTM)
Joincare Pharmaceutical Financial Valuation Multiples
As of April 10, 2026, Joincare Pharmaceutical has market cap of $3B and EV of $1B.
Equity research analysts estimate Joincare Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Joincare Pharmaceutical has a P/E ratio of 14.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 3.8x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBIT | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| P/E | 14.9x | XXX | 15.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Joincare Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Joincare Pharmaceutical Margins & Growth Rates
Joincare Pharmaceutical's revenue in the last 12 month grew by 6%.
Joincare Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Joincare Pharmaceutical's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Joincare Pharmaceutical's rule of X is 31% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Joincare Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (40%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Joincare Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Supernus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tango Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Walvax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Joincare Pharmaceutical M&A Activity
Joincare Pharmaceutical acquired XXX companies to date.
Last acquisition by Joincare Pharmaceutical was on XXXXXXXX, XXXXX. Joincare Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Joincare Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJoincare Pharmaceutical Investment Activity
Joincare Pharmaceutical invested in XXX companies to date.
Joincare Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Joincare Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Joincare Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Joincare Pharmaceutical
| When was Joincare Pharmaceutical founded? | Joincare Pharmaceutical was founded in 1992. |
| Where is Joincare Pharmaceutical headquartered? | Joincare Pharmaceutical is headquartered in China. |
| How many employees does Joincare Pharmaceutical have? | As of today, Joincare Pharmaceutical has over 9K employees. |
| Is Joincare Pharmaceutical publicly listed? | Yes, Joincare Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Joincare Pharmaceutical? | Joincare Pharmaceutical trades under 600380 ticker. |
| When did Joincare Pharmaceutical go public? | Joincare Pharmaceutical went public in 2001. |
| Who are competitors of Joincare Pharmaceutical? | Joincare Pharmaceutical main competitors are Supernus Pharmaceuticals, Tango Therapeutics, Walvax Biotechnology, Apeloa Pharmaceutical. |
| What is the current market cap of Joincare Pharmaceutical? | Joincare Pharmaceutical's current market cap is $3B. |
| What is the current revenue of Joincare Pharmaceutical? | Joincare Pharmaceutical's last 12 months revenue is $2B. |
| What is the current revenue growth of Joincare Pharmaceutical? | Joincare Pharmaceutical revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Joincare Pharmaceutical? | Current revenue multiple of Joincare Pharmaceutical is 0.6x. |
| Is Joincare Pharmaceutical profitable? | Yes, Joincare Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Joincare Pharmaceutical? | Joincare Pharmaceutical's last 12 months EBITDA is $360M. |
| What is Joincare Pharmaceutical's EBITDA margin? | Joincare Pharmaceutical's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Joincare Pharmaceutical? | Current EBITDA multiple of Joincare Pharmaceutical is 3.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.